ETF Holdings Breakdown of MRUS

Stock NameMerus BV
TickerMRUS(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINNL0011606264

News associated with MRUS

Insider Selling: Merus N.V. (NASDAQ:MRUS) COO Sells $1,793,840.00 in Stock
Merus N.V. (NASDAQ:MRUS – Get Free Report) COO Peter B. Silverman sold 34,000 shares of the firm’s stock in a transaction dated Friday, June 20th. The shares were sold at an average price of $52.76, for a total value of $1,793,840.00. The sale was disclosed in a legal filing with the SEC, which is accessible […] - 2025-06-27 08:10:52
Merus N.V. (NASDAQ:MRUS) Receives $84.64 Average Price Target from Brokerages
Merus N.V. (NASDAQ:MRUS – Get Free Report) has been assigned a consensus rating of “Buy” from the fourteen analysts that are currently covering the firm, MarketBeat reports. Twelve equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 1-year target price […] - 2025-06-24 05:36:57
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Buys 14,544 Shares of Merus (NASDAQ:MRUS)
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Merus (NASDAQ:MRUS – Free Report) by 17.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 98,744 shares of the biotechnology company’s stock after purchasing an additional 14,544 shares […] - 2025-06-05 08:13:00
Merus Prices 5.26 Mln Shares At $57/Shr In Public Offering; To Raise Around $300 Mln
(RTTNews) - Merus N.V. (MRUS), a Dutch oncology company developing multispecific antibodies and antibody drug conjugates, Wednesday announced the pricing of an underwritten public offering of around 5.26 million shares, at a price of $57.00 per share. The gross proceeds from the - 2025-06-04 04:56:43
Merus (NASDAQ:MRUS) Earns Buy Rating from Needham & Company LLC
Merus (NASDAQ:MRUS – Get Free Report)‘s stock had its “buy” rating reaffirmed by investment analysts at Needham & Company LLC in a research report issued to clients and investors on Monday,Benzinga reports. They currently have a $75.00 target price on the biotechnology company’s stock. Needham & Company LLC’s price target points to a potential upside […] - 2025-05-21 06:03:18
Merus (NASDAQ:MRUS) Holdings Decreased by The Manufacturers Life Insurance Company
The Manufacturers Life Insurance Company reduced its stake in shares of Merus (NASDAQ:MRUS – Free Report) by 17.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 42,085 shares of the biotechnology company’s stock after selling 9,204 shares during the quarter. […] - 2025-05-12 08:36:50
Tudor Investment Corp ET AL Purchases Shares of 5,075 Merus (NASDAQ:MRUS)
Tudor Investment Corp ET AL bought a new stake in Merus (NASDAQ:MRUS – Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 5,075 shares of the biotechnology company’s stock, valued at approximately $213,000. A number of other institutional investors and hedge […] - 2025-05-11 08:44:52
Tower Research Capital LLC TRC Decreases Stock Holdings in Merus (NASDAQ:MRUS)
Tower Research Capital LLC TRC decreased its stake in shares of Merus (NASDAQ:MRUS – Free Report) by 77.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,668 shares of the biotechnology company’s stock after selling 9,221 shares during the […] - 2025-05-09 08:21:09
Merus (NASDAQ:MRUS) Short Interest Update
Merus (NASDAQ:MRUS – Get Free Report) was the target of a significant decrease in short interest in the month of April. As of April 15th, there was short interest totalling 6,270,000 shares, a decrease of 15.5% from the March 31st total of 7,420,000 shares. Currently, 9.6% of the company’s shares are sold short. Based on […] - 2025-05-05 07:58:56
Merus (NASDAQ:MRUS) Earns “Outperform” Rating from William Blair
William Blair reaffirmed their outperform rating on shares of Merus (NASDAQ:MRUS – Free Report) in a report issued on Monday morning,RTT News reports. Several other analysts have also commented on the stock. Guggenheim reissued a “buy” rating and set a $109.00 target price on shares of Merus in a research note on Friday, March 28th. […] - 2025-04-29 07:54:48
Invesco Ltd. Grows Stock Position in Merus (NASDAQ:MRUS)
Invesco Ltd. lifted its holdings in Merus (NASDAQ:MRUS – Free Report) by 2.2% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 786,365 shares of the biotechnology company’s stock after purchasing an additional 16,712 shares during the period. Invesco Ltd. owned about 1.15% of Merus […] - 2025-04-18 08:18:50
HighTower Advisors LLC Has $337,000 Stock Position in Merus (NASDAQ:MRUS)
HighTower Advisors LLC lifted its position in Merus (NASDAQ:MRUS – Free Report) by 10.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,020 shares of the biotechnology company’s stock after buying an additional 789 shares during the period. HighTower […] - 2025-04-02 07:14:47
Guggenheim Reiterates Buy Rating for Merus (NASDAQ:MRUS)
Merus (NASDAQ:MRUS – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at Guggenheim in a report issued on Tuesday,Benzinga reports. They presently have a $109.00 target price on the biotechnology company’s stock. Guggenheim’s price objective indicates a potential upside of 131.91% from the company’s previous close. Other research analysts also recently […] - 2025-03-20 06:55:00
Bank of America Has Lowered Expectations for Merus (NASDAQ:MRUS) Stock Price
Merus (NASDAQ:MRUS – Get Free Report) had its target price lowered by analysts at Bank of America from $73.00 to $70.00 in a note issued to investors on Monday,Benzinga reports. The firm currently has a “buy” rating on the biotechnology company’s stock. Bank of America‘s price objective indicates a potential upside of 47.12% from the […] - 2025-03-12 06:00:48
HC Wainwright Reaffirms “Buy” Rating for Merus (NASDAQ:MRUS)
Merus (NASDAQ:MRUS – Get Free Report)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They currently have a $85.00 price objective on the biotechnology company’s stock. HC Wainwright’s price target would suggest a potential upside of 90.41% from the stock’s previous close. […] - 2025-03-05 06:32:51
William Blair Predicts Merus’ FY2028 Earnings (NASDAQ:MRUS)
Merus (NASDAQ:MRUS – Free Report) – William Blair issued their FY2028 EPS estimates for Merus in a report issued on Friday, February 28th. William Blair analyst M. Phipps expects that the biotechnology company will post earnings per share of ($3.58) for the year. William Blair has a “Outperform” rating on the stock. The consensus estimate […] - 2025-03-04 08:28:57
Merus (NASDAQ:MRUS) Given New $83.00 Price Target at Needham & Company LLC
Merus (NASDAQ:MRUS – Free Report) had its price objective lowered by Needham & Company LLC from $85.00 to $83.00 in a research note released on Friday morning,Benzinga reports. The firm currently has a buy rating on the biotechnology company’s stock. A number of other equities analysts have also recently commented on the company. The Goldman […] - 2025-03-03 06:54:51
Merus (NASDAQ:MRUS) Shares Purchased by State of New Jersey Common Pension Fund D
State of New Jersey Common Pension Fund D grew its holdings in shares of Merus (NASDAQ:MRUS – Free Report) by 29.0% during the 4th quarter, HoldingsChannel reports. The firm owned 48,268 shares of the biotechnology company’s stock after buying an additional 10,842 shares during the period. State of New Jersey Common Pension Fund D’s holdings […] - 2025-02-24 08:42:49
Analysts Set Merus (NASDAQ:MRUS) PT at $85.92
Shares of Merus (NASDAQ:MRUS – Get Free Report) have been assigned a consensus recommendation of “Buy” from the sixteen research firms that are covering the stock, MarketBeat reports. Fourteen equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average twelve-month price […] - 2025-02-19 06:46:55
KBC Group NV Has $2.41 Million Stake in Merus (NASDAQ:MRUS)
KBC Group NV raised its position in Merus (NASDAQ:MRUS – Free Report) by 4,583.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 57,234 shares of the biotechnology company’s stock after purchasing an additional 56,012 shares during the quarter. KBC Group NV’s holdings in […] - 2025-02-02 09:28:57

MRUS institutional holdings

The following institutional investment holdings of MRUS have been identified

Date ETF ISIN/Name Num Shares Book value
2025-06-26 IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc)) 33,586USD 1,786,103
2025-06-26 IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc) 20,768USD 1,104,442
2025-06-26 IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc)) 77,842USD 4,139,638
2025-06-26 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 34,538USD 1,836,731
2025-06-26 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 34,538USD 1,836,731
2025-06-26 IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc)) 586USD 31,163
Total =201,858 USD 10,734,808
Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.